Impact of oxaliplatin-induced neuropathy: A patient perspective

Supportive Care in Cancer

Volumn 20, Issue 11, 2012, Pages 2959-2967

  Bennett, Barbara K ^a   Park, Susanna B ^b   Lin, Cindy S Y ^a   Friedlander, Michael L ^c   Kiernan, Matthew C ^b   Goldstein, David ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Chemotherapy; Neuropathy; Oxaliplatin; Qualitative analysis

Indexed keywords

OXALIPLATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; NERVE CONDUCTION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SELF EVALUATION; SENSORY NEUROPATHY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84868375308     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1428-5     Document Type: Article

References (42)

1. Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351 (see comment)
2. Cavaliere R, Schiff D (2006) Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep 6:218-226
3. Park SB, Krishnan AV, Lin CSY et al (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081-3094
4. Coleman MP, Quaresma M, Berrion F et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9:730-756
5. Cersosimo RJ (2005) Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39:128-135
6. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116
7. Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30:5-13
8. Gamelin E, Gamelin L, Bassi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29:21-33
9. Argyriou AA, Polychronopoulos P, Iconomou G et al (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Revi 34:368-377
10. Hausheer FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15-49
11. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
12. Park SB, Goldstein D, Lin CS-Y et al (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27:1243-1249
13. Park SB, Lin CS, Krishnan AV et al (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 3:2712-2723
14. Park SB, Lin CSY, Krishnan AVet al (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16:708-716
15. Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205-2211
16. Pietrangeli A, Leandri M, Terzoli E et al (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56:13-16
17. Ganz PA (2003) Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory. Eur J Cancer 39:2136-2141
18. Postma TJ, Heimans JJ, Muller MJ et al (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739-744
19. Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapyinduced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479-494
20. Basch E, Iasonos A, McDonough T et al (2006) Patient versus clinical symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903-909
21. Dunlap B, Paice JA (2006) Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 4:398-399
22. Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509-513
23. Shimozuma K, Ohashi Y, Takeuchi A et al (2009) Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17:1483-1491
24. Kopec JA, Land SR, Cecchini RS et al (2006) Validation of a selfreported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4:W1-W8
25. Mays N, Pope C (1995) Qualitative research: rigour and qualitative research. BMJ 311:109-112
26. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181
27. Cleeland CS, Farrar JT, Hausheer FH (2010) Assessment of cancer-related neuropathy and neuropathic pain. Oncologist 15 (Suppl 2):13-18
28. Kuroi K, Shimozuma K, Ohashi Yet al (2009) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 Study). Support Care Cancer 17:1071-1080
29. Riebandt G, Rodabaugh KJ, Pietkiewicz J et al (2011) Prospective analysis of chemotherapy-induced neuropathy in patients with gynecologic malignancies. J Clin Oncol 29(suppl) abstract e 19737
30. Bennett B, Goldstein D, Friedlander M et al (2007) The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study. J Pain Symptom Manag 34:126-135
31. Kimura J (1983) Electrodiagnosis in diseases of nerve and muscle. F.A. Davis, Philadelphia
32. NVivo (2006) Qualitative data analysis software (version 7). In Edition QSR International Pty, Ltd.
33. Lim J, Macluran M, Price M et al (2004) Short- and Long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer. J Genet Couns 13:115-133
34. Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56:323-331
35. Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13:1389-1391
36. Tofthagen C (2010) Patient perceptions associated with chemotherapyinduced peripheral neuropathy. Clin J Oncol Nurs 14:22-28
37. Hile ES, Fitzgerald GK, Studenski SA (2010) Persistent mobility disability after neurotoxic chemotherapy. Phys Ther 90:1649-1657
38. Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA, The J Am Med Assoc 273:59-65
39. Williams JBW, Kobak KA, Bech P et al (2008) The GRIDHAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol 23:120-129
40. Cavaletti G, Frigeni B, Lanzani F et al (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12:210-215
41. Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22
42. Blinman P, Duric V, Nowak AK et al (2010) Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? Eur J Cancer 46:1800-1807